Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Insight Molecular Diagnostics Inc

IMDX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.32

▲ +16.44%

Market Cap $141.37M · Vol 117.27K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$141.37M

Micro Cap

Div Yield

N/A

EPS Growth

+47.27%

YoY

RSI (14)

44.24

Momentum

Beta

1.79

vs Market

52W High

$8.51

49.24% below

52W Low

$2.35

83.83% above

Volume

117.27K

Avg 73.55K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

79.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Insight Molecular Diagnostics Inc (IMDX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IMDX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-10.56%

-3.14%

-32.71%

-22.44%

YTD

-42.40%

+80.00%

+29.34%

-95.18%

Financials & Valuation

TTM · Annual

Total Revenue	$4.06M
Net Income	$-50,222,000.00
Revenue Growth (YoY)	-53.86%
Gross Margin	56.67%
Operating Margin	-752.03%
Net Profit Margin	-1,238.52%
ROE	N/A
ROA · ROIC	-165.10% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	56.37
P/B	N/A
P/FCF	N/A
EPS Growth	+47.27%
Outstanding Shares	32.72M

Technical Indicators

50-Day SMA	$5.09
200-Day SMA	$5.43
RSI (14)	44.24
Beta	1.79
52-Week High	$8.51
52-Week Low	$2.35

Volume Today	117.27K
Avg Daily Volume (30D)	73.55K
Relative Volume	1.59x
Volatility (10D)	136.49
Volatility (30D)	100.53
Free Float	79.00%

Analyst Consensus

BUY

Current Price $4.32

Mean Target $8.33

52W Low$2.35 52W High$8.51

Current

Target

$2.35 $8.51

Current Analyst target

+92.90% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG008P5VFW0

ISINUS68235C2061

CountryUnited States of America

Sub-IndustryBio Diagnostics & Testing

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

ADPT Adaptive Biotechnologies Corp +1.14% VCYT Veracyte Inc -3.17% IOVA Iovance Biotherapeutics Inc +7.06% 300676.SZ BGI Genomics Co Ltd -3.10% CDNA CareDx Inc -4.35%

Company Profile

Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.